Promote Deep-tech and Healthtech innovation by investing in breakthrough technologies and providing support from industry leaders while changing the fund’s traditional investments paradigm and allowing the fund investors to benefit from better liquidity and transparency.
A vehicle for community investment, providing projects a funding platform.
Investors will benefit from better liquidity
PeaksDA Members are involved in the investment decision-making process.
No time limitation for investments and Exits
Almost no geographical limitations
PeaksDA.vc offers a full complex of services: starting with a project “package” and up to the stage of attracting finances and startup’s entering the market.
Our Team
CEO and Managing partner at Compass Ventures Group and former President of the Advertising & Media division at Amdocs and senior manager in various leading multinational companies, he is an experienced international executive manager and investor with an impressive track record in technology companies, specializing in fund management and leading global investment projects in technology and innovation. His expertise includes sourcing cutting-edge technology products and solutions in a range of sectors, and bringing them to market, with a focus on international markets.
Operational Experience
Founder and CEO of Peaks Ventures with over 30 years’ management experience in the biotech industry; scientific development and building business strategies.
Served as the Head of Life Science in Compass Ventures Group, as well as co-founding and CEO of AIT and BioMimic Pharma, two prominent cancer immunotherapy companies that were acquired by US companies. She has also worked with the first leading Israeli biotech companies; Biotechnology General and Interpharm.
Earned her PhD in Biochemistry and Molecular Biology from the Weizmann Institute of Science and completed her post-doctorate at the University of California, Berkeley.
CEO of EverFlow and a Blockchain serial entrepreneur with extensive experience in the start-up sphere.
Over 15 years of executive roles at tech companies, with a broad network of contacts in various vertical markets globally.
An early stage investor in several ventures in the fintech market.
Mr. Zeev Holtzman is CEO of Giza fund with over 20 years’ experience in the Private Equity and Investment Banking sectors. At Giza Mr. Holtzman focuses on strategy, networking, deal sourcing, and the company’s activities in Asia and Poland while acting as Chairman of the GPV-Poland Investment Committee.
CEO and Managing partner at Compass Ventures Group and former President of the Advertising & Media division at Amdocs and senior manager in many leading multinational companies, he is an experienced international executive manager and investor with an impressive track record in technology companies, specializing in fund management and leading global investment projects in technology and innovation. His expertise includes sourcing cutting-edge technology products and solution in a range of sectors, and bringing them to market, with a focus on international markets.
CEO of Peaks Ventures & former Co-Founder & CEO of AIT and BioMimic Pharma; both have been acquired by US companies. She has worked for leading Israeli biotech companies and has been involved in establishing a number of start-up companies. She has served as an advisor for investors and accelerators in the life science field in Israel.
PeaksDA experienced team identifies and conducts research on hundreds of cutting-edge technologies opportunities.
Join us to access these opportunities
An innovative immunotherapy company
Cancer is a major cause of death worldwide. There is a huge unmet need for novel cancer therapies, but the greatest challenge is the lack of good targets.
Cancer cells shield themselves with sugar-coating to evade the immune system. Cell surface glycans have different abnormal structures that are not found in healthy cells. So the cancer cell sugar-coat is actually different, generating carbohydrate-neoantigens (cAg) that are excellent targets for cancer therapy.
Glyconia developed an innovative technology targeting cAgs on cancer cells with engineered CAR-T, turning them into cancer-killing machines for optimal efficacy, particularly in solid tumors.
Body Mole Mapping and Tracking system
Marpé Technologies is a science based company developing innovative scanners for early detection of skin cancer.
Prototype scanners are operating at the Tel Aviv Sourasky Medical Center and the Bnei Zion Medical Center in Haifa, both leading hospitals in Israel, indicating the superior features of Marpe’s technology.
ATLASense Biomed
Platforms
ATLASense Platform is the only personalized, continuous, and comprehensive health surveillance system to assist in the prevention of deterioration by detecting unique early warning signs both in-hospital and at home.